|
Published in Volume
99, Issue 5 (March 1,1997)
J. Clin. Invest.
99(5):
953-961 (1997).
doi:10.1172/JCI119260.
Copyright ©
1997, The American Society for
Clinical Investigation.
Research Article
Complex genetic contribution of the Apo AI-CIII-AIV gene cluster to familial combined hyperlipidemia. Identification of different susceptibility haplotypes.
G M Dallinga-Thie,
M van Linde-Sibenius Trip,
J I Rotter,
R M Cantor,
X Bu,
A J Lusis and
T W de Bruin
Department of Medicine and Endocrinology, University Hospital, Utrecht, The Netherlands. g.m.dallingathie@digd.azu.nl
Published March 1,
1997
Familial combined hyperlipidemia (FCH) is a common genetic lipid disorder in Western societies. In a recent report (Dallinga-Thie, G.M., X.D. Bu, M. van Linde-Sibenius Trip, J.I. Rotter, A.J. Lusis, and T.W.A. de Bruin. J. Lipid Res., 1996, 36:136-147) we have studied three restriction enzyme polymorphisms: XmnI, and MspI sites 5' of the apo AI gene and SstI site in the 3' untranslated region of exon 4 of the apo CIII gene in 18 FCH pedigrees, including 18 probands, 178 hyperlipidemic relatives, 210 normolipidemic relatives, and 176 spouses. DNA variations in the apo AI-CIII-AIV gene cluster had a modifying effect on plasma triglycerides, LDL cholesterol, and apolipoprotein CIII levels. In this study, combinations of haplotypes were analyzed to further characterize their interactions and effect on the expression of severe hyperlipidemia in FCH subjects. A specific combination of haplotypes with one chromosome carrying the X1M1S2 (1-1-2) haplotype and the other the X2M2S1 haplotype (2-2-1) was significantly more frequent in hyperlipidemic relatives (6%) than in normolipidemic relatives (3%) and spouses (0.5%). Associated with this combination of haplotypes were significantly elevated plasma cholesterol (P < 0.0001), triglycerides (P < 0.0001), and apo CIII (P < 0.001) levels when compared to the wild type combination of haplotypes 1-1-1/1-1-1. The only spouse with this specific combination of haplotypes showed a severe hyperlipidemic phenotype, similar to FCH. Furthermore, nonparametric sibpair linkage analysis revealed significant linkage between these markers in the gene cluster and the FCH phenotype (MspI P = 0.0088, SstI P = 0.044, and XMS haplotype P = 0.037). The present findings confirm that the apo AI-CIII-IV gene cluster contributes to the FCH phenotype, but this contribution is genetically complex. An epistatic interaction between different haplotypes of the gene cluster was demonstrated. The S2 allele on one haplotype was synergistic to the X2M2 allele on the other haplotype in its hyperlipidemic effect. Therefore, two different susceptibility loci exist in the gene cluster, demonstrating the paradigm of complex genetic contribution to FCH.
|
|
Articles that cite this article:
Apolipoprotein E Polymorphism Influences Lipid Phenotypes in Chinese Families With Familial Combined Hyperlipidemia Wei-Dong Pei, Yan-Hong Zhang, Yu-Hua Sun, Yu-Chun Gu, Yan-Fen Wang, Chao-Yang Zhang, Jian Zhang, Li-Sheng Liu, Ru-Tai Hui, Yu-Qing Liu Circ J 70(12):1606. [CrossRef] Bradley Aouizerat, Hooman Allayee, Jackie Bodnar, Kelly Krass, Leena Peltonen, Tjerk De bruin, Jerome Rotter, Aldons Lusis Curr Opin Lipidol 10(2):113. [CrossRef]
Linkage of familial combined hyperlipidaemia to chromosome 1q21–q23 Paivi Pajukanta, Ilpo Nuotio, Joseph D. Terwilliger, Kimmo V.K. Porkka, Kati Ylitalo, Jussi Pihlajamäki, Aki J. Suomalainen, Ann-Christine Syvänen, Terho Lehtimäki, Jorma S.A. Viikari Nat Genet 18(4):369. [CrossRef] Effect of SstI Polymorphism of the Apolipoprotein CIII Gene and Environmental Factors on Risks of Hypertriglyceridemia in Taiwan Aborigines Meng-Chuan Huang, Tsu-Nai Wang, Yi-Ling Liu, Te-Hsiung Pa, Hung-Ping Tu, Yi-Chia Huang, Wen-Tsan Chang, Ying-Chin Ko Circ J 70(8):1030. [CrossRef] APOA1 polymorphisms are associated with variations in serum triglyceride concentrations in hypercholesterolemic individuals Simone C. Sorkin, Francisco J. Forestiero, Mario H. Hirata, Elizabeth C. R. Guzmán, Selma A. Cavalli, Marcelo C. Bertolami, Luis A. Salazar, Rosario D. C. Hirata cclm 43(12):1339. [CrossRef] Study of apolipoproteinc3 Sstl polymorphism in healthy volunteers from Northern India S. Chhabra, D. P. Agarwal, S. Vasisht, K. Luthra, R. Narang, S. C. Manchanda, L. M. Srivastava, N. Das Indian J Clin Biochem 18(2):34. [CrossRef] Molecular Diagnostics for Cardiovascular Disease Chi-Pui Pang cclm 36(8):605. [CrossRef] Harald Funke, Gerd Assmann Curr Opin Lipidol 10(3):285. [CrossRef]
Two newly identified SNPs in the APO AI-CIII intergenic region are strongly associated with familial combined hyperlipidaemia M. Groenendijk, R. M. Cantor, H. Funke, G. M. Dallinga-thie Eur J Clin Invest 31(10):852. [CrossRef] Contribution of Chromosome 1q21-q23 to Familial Combined Hyperlipidemia in Mexican Families A. Huertas-vazquez, J. P. Del rincon, S. Canizales-quinteros, L. Riba, G. Vega-hernandez, S. Ramirez-jimenez, M. Auron-gomez, F. J. Gomez-perez, C. A. Aguilar-salinas, M. T. Tusie-luna Ann Hum Genet 68(5):419. [CrossRef] Effects of apolipoprotein A-I genetic variations on plasma apolipoprotein, serum lipoprotein and glucose levels IA Larson, JM Ordovas, JR Barnard, MM Hoffmann, G Feussner, S Lamon-fava, EJ Schaefer Clin Genet 61(3):176. [CrossRef] Support for linkage of familial combined hyperlipidemia to chromosome 1q21-q23 in Chinese and German families Weidong Pei, Heike Baron, Bertram Muller-myhsok, Hans Knoblauch, Said Ali al-yahyaee, Rutai Hui, Xigui Wu, Lisheng Liu, Andreas Busjahn, Friedrich C Luft Clin Genet 57(1):29. [CrossRef] Neil Shachter Curr Opin Lipidol 12(3):297. [CrossRef]
Genetics of familial combined hyperlipidemia Päivi Pajukanta, Kimmo V. K. Porkka Curr Atheroscler Rep 1(1):79. [CrossRef] GENETICS OF LIPOPROTEIN ABNORMALITIES ASSOCIATED WITH CORONARY HEART DISEASE SUSCEPTIBILITY Jan L. Breslow Annu Rev Genet 34(1):233. [CrossRef] Associations among Race/Ethnicity, ApoC-III Genotypes, and Lipids in HIV-1-Infected Individuals on Antiretroviral Therapy Andrea S. Foulkes, David A. Wohl, Ian Frank, Elaine Puleo, Stephanie Restine, Megan L. Wolfe, Michael P. Dube, Pablo Tebas, Muredach P. Reilly Plos Med 3(3):e52. [CrossRef]
|